Haoran Li1, Haider Samawi1, Daniel Y C Heng2. 1. Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada. 2. Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada. Electronic address: Daniel.heng@albertahealthservices.ca.
Abstract
BACKGROUND: Over the last decade, the treatment landscape of metastatic renal cell carcinoma (mRCC) has evolved tremendously. The outcome of patients with mRCC has been improved since the advent of targeted therapy. OBJECTIVE: In this review, we address the use of prognostic schema in the era of targeted treatment. This article summarizes the current available prognostic models and the evidence to support their use in clinical settings. CONCLUSION: Prognostic models can help guide clinicians in their decision making, as they have been validated in the first- and second-line targeted therapy settings as well as in non-clear cell mRCC. Prognostic factors are important in patient counseling, clinical trial stratification, and therapy planning. Very selected favorable-risk patients with minimal bulk and slow-growing disease could potentially be observed before needing treatment. Patients with poor-risk disease may be eligible for treatment with temsirolimus. Patients with a very poor prognosis may not be suitable candidates for cytoreductive nephrectomy. New biomarkers are on the horizon, though their roles need to be validated and their additive contribution to improve existing prognostic models examined.
BACKGROUND: Over the last decade, the treatment landscape of metastatic renal cell carcinoma (mRCC) has evolved tremendously. The outcome of patients with mRCC has been improved since the advent of targeted therapy. OBJECTIVE: In this review, we address the use of prognostic schema in the era of targeted treatment. This article summarizes the current available prognostic models and the evidence to support their use in clinical settings. CONCLUSION: Prognostic models can help guide clinicians in their decision making, as they have been validated in the first- and second-line targeted therapy settings as well as in non-clear cell mRCC. Prognostic factors are important in patient counseling, clinical trial stratification, and therapy planning. Very selected favorable-risk patients with minimal bulk and slow-growing disease could potentially be observed before needing treatment. Patients with poor-risk disease may be eligible for treatment with temsirolimus. Patients with a very poor prognosis may not be suitable candidates for cytoreductive nephrectomy. New biomarkers are on the horizon, though their roles need to be validated and their additive contribution to improve existing prognostic models examined.
Authors: Oscar Rodriguez Faba; Sabine D Brookman-May; Estefania Linares; Alberto Breda; Francesca Pisano; José Daniel Subiela; Francesco Sanguedolce; Maurizio Brausi; Joan Palou Journal: World J Urol Date: 2017-07-12 Impact factor: 4.226
Authors: Hana Mlcochova; Tana Machackova; Anja Rabien; Lenka Radova; Pavel Fabian; Robert Iliev; Katerina Slaba; Alexandr Poprach; Ergin Kilic; Michal Stanik; Martina Redova-Lojova; Marek Svoboda; Jan Dolezel; Rostislav Vyzula; Klaus Jung; Ondrej Slaby Journal: Sci Rep Date: 2016-08-23 Impact factor: 4.379
Authors: Meijun Du; Karthik V Giridhar; Yijun Tian; Michael R Tschannen; Jing Zhu; Chiang-Ching Huang; Deepak Kilari; Manish Kohli; Liang Wang Journal: Oncotarget Date: 2017-07-22